WHAT IS CBG
CBG (cannabigerol) is called the "mother cannabinoid" because its acid-form precursor CBGa is the upstream molecule from which most other cannabinoids are enzymatically synthesized during plant growth.
By the time cannabis reaches harvest, most CBGa has already converted into CBDa, THCa, or CBCa via the plant’s enzymes. This is why mature cannabis typically contains less than 1% CBG. However, some cultivators have developed CBG-dominant cultivars that produce 10%+ CBG by harvesting early or using cultivars with reduced enzyme expression.
CBG is non-psychoactive and under research for anti-inflammatory, antibacterial, and neuroprotective activity. Commercial CBG products are typically marketed alongside CBD for wellness use.
EFFECTS + RESEARCH
CBG shows preliminary research evidence for anti-inflammatory effects (potentially relevant to inflammatory bowel disease), antibacterial activity (effective against MRSA in lab studies), and neuroprotective effects in models of Huntington’s disease.
Clinical translation is early. Most CBG research is preclinical (animal models, cell cultures). Human clinical trials are limited.
Subjectively, CBG users report mild focus enhancement and reduced anxiety without the sedation of CBD. Effects are subtle compared to THC.
